TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8569263
Drug: Western drugs
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western drugs (WM group)
Study: 21918063
Drug: Fortified choco-malt
Normalized name: malt extract
DrugBank: Barley malt syrup (DB14601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified choco-malt beverage powder (40 g daily for 120 days)
Study: 21918063
Drug: Matched energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched energy equivalent unfortified placebo (40 g daily for 120 days)
Study: 11324210
Drug: Narrow-diameter self-tapping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-diameter self-tapping implants (3.25-mm)
Study: 11324210
Drug: Standard-diameter self-tapping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-diameter self-tapping implants (3.75-mm)
Study: 3076661
Drug: Nisoldipine 5
Normalized name: nisoldipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 5 mg/day
Study: 3076661
Drug: Nisoldipine (2.5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (2.5-20 mg/day)
Study: 3076661
Drug: Nisoldipine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (twice daily)
Study: 3076661
Drug: Nisoldipine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (active drug)
Study: 31490292
Drug: Superior trunk
Normalized name: Sus scrofa superior gastric plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superior trunk block (15 ml of 0.5% ropivacaine and 5 μg · ml epinephrine)
Study: 31490292
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block (15 ml of 0.5% ropivacaine and 5 μg · ml epinephrine)
Study: 28503777
Drug: 8000 PNU/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8000 PNU/mL
Study: 28503777
Drug: 6000 PNU/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6000 PNU/mL
Study: 28503777
Drug: >8000 PNU/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: >8000 PNU/mL
Study: 25182544
Drug: Ecallantide 10
Normalized name: ecallantide 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecallantide 10 mg
Study: 25182544
Drug: Ecallantide 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecallantide 30 mg
Study: 25182544
Drug: Ecallantide 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecallantide 60 mg
Study: 24445367
Drug: TDF co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF co-administered with lopinavir/ritonavir (LPV/r)
Study: 24445367
Drug: TDF co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF co-administered with nevirapine (NVP)
Study: 19948614
Drug: PEG (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG (1.5 g/kg per day for 6 days)
Study: 9679846
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (200 microg once daily for 2 weeks)
Study: 9679846
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray (once daily for 2 weeks)
Study: 7982695
Drug: Intensive case
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive case management provided by an assertive community treatment team
Study: 4237796
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg tetracycline hydrochloride twice daily for three months
Study: 31523801
Drug: Bilateral quadratus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral quadratus lumborum block (40 ml levobupivacaine 0.25%)
Study: 25270273
Drug: AR‐13324 ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR‐13324 ophthalmic solution 0.01%
Study: 25270273
Drug: AR‐13324 ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR‐13324 ophthalmic solution 0.02%
Study: 23254324
Drug: Wound infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infusion catheter (WIC)
Study: 21598351
Drug: tirofiban (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirofiban (high-dose bolus 25 μg/kg plus 12-hr infusion 0.15 μg/kg/min)
Study: 31801490
Drug: Pre‐oral carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐oral carbohydrate load (preOp™)
Study: 18063490
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous combined HRT (LD-HRT) containing 1mg estradiol + 0.5 mg norethisterone acetate
Study: 18063490
Drug: Ultra low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra low dose hormone replacement therapy (Ultra-LD-HRT) containing 0.5 mg of 17beta-estradiol and 0.25 mg of norethisterone acetate
Study: 18063490
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only 1000 mg of calcium per day
Study: 16896912
Drug: Rituximab added
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab added to high-dose therapy (HDT)
Study: 8603758
Drug: A balanced
Normalized name: DuetDHA Balanced
DrugBank: DL-alpha tocopheryl acetate (DB14477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A balanced amino acid solution infused at 0.5 mg x kg⁻¹ x min⁻¹
Study: 8603758
Drug: A balanced
Normalized name: DuetDHA Balanced
DrugBank: DL-alpha tocopheryl acetate (DB14477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A balanced amino acid solution infused at 1.0 mg x kg⁻¹ x min⁻¹
Study: 8603758
Drug: A balanced
Normalized name: DuetDHA Balanced
DrugBank: DL-alpha tocopheryl acetate (DB14477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A balanced amino acid solution infused at 2.0 mg x kg⁻¹ x min⁻¹
Study: 8603758
Drug: A balanced
Normalized name: DuetDHA Balanced
DrugBank: DL-alpha tocopheryl acetate (DB14477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A balanced amino acid solution infused at 4.0 mg x kg⁻¹ x min⁻¹
Study: 8603758
Drug: A balanced
Normalized name: DuetDHA Balanced
DrugBank: DL-alpha tocopheryl acetate (DB14477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A balanced amino acid solution infused at 6.0 mg x kg⁻¹ x min⁻¹
Study: 7024866
Drug: Diflunisal (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (750 mg/day)
Study: 27760701
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of specialized treatment for a total of five years
Study: 27760701
Drug: Discontinuation after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation after the standard two-year treatment
Study: 22843310
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using a 980-nm diode-laser at 300 mW for 180 seconds (54 J) applied intraorally and extraorally immediately after surgery and at 24 hours.
Study: 16863608
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg once daily for 9 months)
Study: 12623291
Drug: Tenidap 40
Normalized name: tenidap
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap 40 mg
Study: 12623291
Drug: Tenidap 120
Normalized name: tenidap
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap 120 mg
Study: 12623291
Drug: Tenidap 40
Normalized name: tenidap
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap 40 mg and Tenidap 120 mg
Study: 10837286
Drug: High isoflavone
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High isoflavone diet (128.7 mg/d)
Study: 1441728
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A liposome vaccine
Study: 1441728
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of vaccine on the same day in one injection
Study: 30464447
Drug: Endobronchial coil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial coil treatment (ECT)
Study: 27585745
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg iron daily (Group A)
Study: 27585745
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg or 0 mg iron daily based on weekly hepcidin screening (Group B)
Study: 27585745
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg or 0 mg iron daily based on weekly hepcidin screening (Group C)
Study: 24439986
Drug: DAPT (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (aspirin and clopidogrel for 12 months, n = 314)
Study: 15997257
Drug: Transcutaneous Electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous Electrical Nerve Stimulation (TENS) therapy for 30 minutes
Study: 15997257
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of paracetamol
Study: 11922547
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (300 ml)
Study: 10612504
Drug: Timolol hemihydrate
Normalized name: Timolol Hemihydrate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol hemihydrate 0.5% solution
Study: 10612504
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate gel 0.5%
Study: 1593574
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg OD
Study: 1593574
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg OD
Study: 30346543
Drug: Tablet-based bedside
Normalized name: Bedside-Care
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-based bedside educational intervention; provided for 1 day during inpatient stay
Study: 30346543
Drug: Tablet-based bedside
Normalized name: Bedside-Care
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-based bedside educational intervention
Study: 24840045
Drug: Edivoxetine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edivoxetine 0.2 mg/kg/day
Study: 24840045
Drug: Edivoxetine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edivoxetine 0.3 mg/kg/day
Study: 24840045
Drug: OROS MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OROS MPH (18-54 mg/day)
Study: 24840045
Drug: Edivoxetine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edivoxetine 0.1 mg/kg/day
Study: 24840045
Drug: Edivoxetine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edivoxetine treatment
Study: 18695931
Drug: 29.3 mg
Normalized name: bupivacaine 29.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 29.3 mg THC cigarette
Study: 18695931
Drug: 49.1 mg
Normalized name: AVOBENZONE 29.43 mg in 1 mL / HOMOSALATE 98.1 mg in 1 mL / OCTISALATE 49.1 mg in 1 mL / OCTOCRYLENE 49.1 mg in 1 mL TOPICAL LOTION [Australian Gold Broad Spectrum SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 49.1 mg THC cigarette
Study: 18695931
Drug: 69.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 69.4 mg THC cigarette
Study: 16169791
Drug: Recent hospitalization,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent hospitalization, more than one ED visit for asthma in the past year, parent's assessment of 'very severe' asthma, current daily use of a controller medication
Study: 16169791
Drug: Parental beliefs
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental beliefs about the importance of daily asthma medications and understanding causes of asthma attacks
Study: 11962676
Drug: Chronotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronotherapy with 5‐fluorouracil (5‐FU), leucovorin, and oxaliplatin (L‐OHP)
Study: 11962676
Drug: Chronotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronotherapy with 5‐FU, leucovorin, and L‐OHP
Study: 8926908
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg nocte
Study: 8926908
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg nocte
Study: 1888829
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole o.m. (n = 12)
Study: 1888829
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole o.m. (n = 12)
Study: 27785010
Drug: Indacaterol (IND)
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol (IND) 150 μg once daily
Study: 27785010
Drug: Glycopyrronium (GLY)
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium (GLY) 50 μg once daily
Study: 27785010
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (TIO) 18 μg once daily
Study: 24885904
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy (DBT) for 16 weeks
Study: 17210507
Drug: Sunflower therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower therapy
Study: 12234889
Drug: Lyophilised fluorescein
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lyophilised fluorescein (68 micro g)
Study: 12234889
Drug: Conventional fluorescein
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional fluorescein ophthalmic solution (0.17%)
Study: 31558739
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran supplementation (1-5 g/day)
Study: 27485237
Drug: Sildenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20 mg, oral, 3 times daily for 4 weeks)
Study: 25885010
Drug: Parent training
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent training plus stimulant plus risperidone (augmented treatment)
Study: 25885010
Drug: Parent training
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent training plus stimulant plus placebo (basic treatment)
Study: 24499495
Drug: NRL001 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL001 2 g suppositories (7.5, 10, 12.5 or 15 mg)
Study: 22034996
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg intravenous ibutilide
Study: 19395948
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses LAIV
Study: 19395948
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose LAIV
Study: 19395948
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose LAIV (year 2)
Study: 19395948
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses LAIV (year 1)
Study: 15649287
Drug: ISO (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISO (40 mg) tablets
Study: 15649287
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C (25 mg) and E (5 mg) tablets
Study: 15649287
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (vehicle only)
Study: 11452938
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) with 10 Gy to the flank at age 4 years
Study: 11452938
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) with 15-24 Gy at a mean age of 55 months
Study: 11452938
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) doses under 15 Gy at a mean age of 83 months
Study: 8207741
Drug: Perindopril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril plus hydrochlorothiazide (HCTZ) 12.5 mg once daily
Study: 8207741
Drug: Perindopril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril plus nifedipine SR 10 mg twice daily
Study: 810098
Drug: Urokinase‐Heparin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase‐Heparin combination (2,700,000 CTA units of Urokinase and 240 mg of Heparin)
Study: 810098
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (300 mg Heparin)
Study: 810098
Drug: Urokinase‐Heparin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase‐Heparin combination
Study: 31243228
Drug: High-concentration insulin
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration insulin glargine (U300G)
Study: 22056739
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) with cisplatin (30 mg/m² weekly during RT)
Study: 9071201
Drug: Indobufen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (400 mg per day)
Study: 9071201
Drug: Pentoxifylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (600 mg per day)
Study: 3505530
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg of monosodium glutamate (MSG)
Study: 25011439
Drug: OxMdG (oxaliplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxMdG (oxaliplatin, 5-fluorouracil, and folic acid) with SIRT (Selective Internal Radiation Therapy)
Study: 21902854
Drug: Mindfulness‐Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness‐Based Cognitive Therapy (MBCT) - 8 sessions of 1 hour each
Study: 11084174
Drug: Transcervical analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical analgesia with 75 mg of bupivacaine
Study: 11084174
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 75 mg of bupivacaine to the fallopian tubes
Study: 8227469
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg three times a day
Study: 8227469
Drug: Naproxen 375
Normalized name: naproxen 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 375 mg twice a day
Study: 26668251
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg balugrastim
Study: 26668251
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg balugrastim
Study: 26668251
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg pegfilgrastim
Study: 19862815
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg orally twice daily plus subcutaneous IFN 0.5 million U (MU) twice daily
Study: 15182266
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (antibiotics, ribavirin, corticosteroids, pulsed methylprednisolone if needed)
Study: 11680329
Drug: Titrated oral
Normalized name: magnesium citrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oral misoprostol solution (20 μg, increased to 40 μg after three doses, administered every 2 hours)
Study: 24112746
Drug: Titrated oral
Normalized name: magnesium citrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oral misoprostol solution
Study: 6148382
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg propranolol
Study: 9675624
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg per day bopindolol
Study: 2512630
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition with amino acids (1000 ml of Vamin 14g N/l)
Study: 2512630
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition without amino acids
Study: 28619129
Drug: Levamlodipine besylate
Normalized name: Levamlodipine besylate
DrugBank: Levamlodipine (DB09237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamlodipine besylate 2.5-mg tablet (test)
Study: 28619129
Drug: Levamlodipine besylate
Normalized name: Levamlodipine besylate
DrugBank: Levamlodipine (DB09237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamlodipine besylate 2.5-mg marketed counterpart (reference)
Study: 25209926
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daily of self-administered vaginal progesterone
Study: 22936007
Drug: Tideglusib (400,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tideglusib (400, 600, 800, 1,000 mg)
Study: 21349646
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream (group A)
Study: 19906334
Drug: Medical termination
Normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical termination of pregnancy (MTOP) - mifepristone 200 mg orally followed by misoprostol 36-48 hours later
Study: 14762776
Drug: Scheduled infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Scheduled infliximab 10 mg/kg
Study: 14762776
Drug: Scheduled infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Scheduled infliximab 5 mg/kg
Study: 9137509
Drug: MMV chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMV chemotherapy (mitomycin C, methotrexate, vincristine) alone
Study: 9137509
Drug: MMV chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMV chemotherapy (mitomycin C, methotrexate, vincristine) with medroxyprogesterone acetate
Study: 9137509
Drug: MMV chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMV chemotherapy (mitomycin C, methotrexate, vincristine) with prednisolone
Study: 8106223
Drug: 6mg buccal
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6mg buccal prochlorperazine one hour before surgery
Study: 28715811
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment (3-month scheduled followed by 9-month pro re nata)
Study: 23621388
Drug: Matrix rhythm
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix rhythm therapy